Spinal muscular atrophy - onasemnogene abeparvovec - authority application form (PB330)

Use this form to apply for PBS-subsidised gene therapy with onasemnogene abeparvovec for patients aged 9 months or under with spinal muscular atrophy.

Page last updated: 1 November 2024.
QC 62483